Anti-VEGFs superior to laser photocoagulation

Article

According to recently published data, anti-VEGF therapy is superior to laser photocoagulation for the treatment of moderate-to-severe visual impairment caused by diabetic macular oedema (DME).

According to recently published data, anti-VEGF therapy is superior to laser photocoagulation for the treatment of moderate-to-severe visual impairment caused by diabetic macular oedema (DME).

The study, performed by Dr Tian Yin Wong et al. (Singapore Eye Research Institute, Singapore National Eye Centre, National University of Singapore, Singapore), was a perspective review of literature on DME treatment modalities. This review included studies published between January 1985 and July 2013.

In this review, the authors found that although laser photocoagulation has been the mainstay treatment for DME for nearly 30 years, more recently there has been increasing evidence demonstrating superior results with anti-VEGF therapy. Also, from large phase II and III trials for ranibizumab, the authors found that visual improvement and safety profiles were favourable towards the anti-VEGF therapy over laser photocoagulation for up to 3 years. Patients were also more likely to experience visual loss with laser treatment.

There were limited studies for other anti-VEGF therapies, such as bevacizumab and aflibercept in DME, however, even in these limited cases the results favoured the anti-VEGF therapeutic option.

For more detailed information please visit the American Journal of Ophthalmology.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.